Evidence map›Paper›PMID 37109414›Full record

ArticleLife (Basel, Switzerland)2023

Diagnosis of Prostate Cancer through the Multi-Ligand Binding of Prostate-Derived Extracellular Vesicles and miRNA Analysis.

Lidia Zabegina, Ilya Zyatchin, Margarita Kniazeva, Andrey Shalaev, Maria Berkut, Vladimir Sharoyko, Vladimir Mikhailovskii, Kirill Kondratov, Sergey Reva, Alexandr Nosov and 1 more

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Lidia ZabeginaSubcellular Technology Lab, Petrov National Medical Research Center of Oncology, 197758 Saint-Petersburg, Russia.ORCID 0000-0003-0827-1641
Ilya ZyatchinDepartment of Oncology No. 6, Pavlov First Medical State University, 197022 Saint-Petersburg, Russia.
Margarita KniazevaSubcellular Technology Lab, Petrov National Medical Research Center of Oncology, 197758 Saint-Petersburg, Russia.
Andrey ShalaevSubcellular Technology Lab, Petrov National Medical Research Center of Oncology, 197758 Saint-Petersburg, Russia.
Maria BerkutSurgical Department of Oncourology, Petrov National Medical Research Center of Oncology, 197758 Saint-Petersburg, Russia.
Vladimir SharoykoDepartment of General and Bioorganic Chemistry, Pavlov First Medical State University, 197022 Saint-Petersburg, Russia.ORCID 0000-0002-3717-0471
Vladimir MikhailovskiiInterdisciplinary Resource Center for Nanotechnology, Saint-Petersburg State University, 199034 Saint-Petersburg, Russia.
Kirill KondratovTranslational Medicine Laboratory, City Hospital No. 40, 197706 Saint-Petersburg, Russia.ORCID 0000-0002-8302-1186
Sergey RevaDepartment of Oncology No. 6, Pavlov First Medical State University, 197022 Saint-Petersburg, Russia.
Alexandr NosovSurgical Department of Oncourology, Petrov National Medical Research Center of Oncology, 197758 Saint-Petersburg, Russia.
Anastasia MalekSubcellular Technology Lab, Petrov National Medical Research Center of Oncology, 197758 Saint-Petersburg, Russia.ORCID 0000-0001-5334-7292
First Pavlov State Medical University of St. Petersburg · RUInstitute of Oncology NN Petrov · RUCity Hospital No. 40 · RUNanosystem (Russia) · RUSt Petersburg University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe development of new non-invasive markers for prostate cancer (PC) diagnosis, prognosis, and management is an important issue that needs to be addressed to decrease PC mortality. Small extracellular vesicles (SEVs) secreted by prostate gland or prostate cancer cells into the plasma are considered next-generation diagnostic tools because their chemical composition might reflect the PC development. The population of plasma vesicles is extremely heterogeneous. The study aimed to explore a new approach for prostate-derived SEV isolation followed by vesicular miRNA analysis.

methodsWe used superparamagnetic particles functionalized by five types of DNA-aptamers binding the surface markers of prostate cells. Specificity of binding was assayed by AuNP-aptasensor. Prostate-derived SEVs were isolated from the plasma of 36 PC patients and 18 healthy donors and used for the assessment of twelve PC-associated miRNAs. The amplification ratio (amp-ratio) value was obtained for all pairs of miRNAs, and the diagnostic significance of these parameters was evaluated.

resultsThe multi-ligand binding approach doubled the efficiency of prostate-derived SEVs' isolation and made it possible to purify a sufficient amount of vesicular RNA. The neighbor clusterization, using three pairs of microRNAs (miR-205/miR-375, miR-26b/miR375, and miR-20a/miR-375), allowed us to distinguish PC patients and donors with sensitivity-94%, specificity-76%, and accuracy-87%. Moreover, the amp-ratios of other miRNAs pairs reflected such parameters as plasma PSA level, prostate volume, and Gleason score of PC.

conclusionsMulti-ligand isolation of prostate-derived vesicles followed by vesicular miRNA analysis is a promising method for PC diagnosis and monitoring.

Indexed as

aptamerdiagnosismiRNAprostate cancersmall extracellular vesicles (SEV)

Identifiers

PMID37109414
PMCPMC10141197
OpenAlexW4361006653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.